Mogelijk gemaakt door Google TranslateTranslate
Oorspronkelijke tekst
Deze vertaling beoordelen
Je feedback wordt gebruikt om Google Translate te verbeteren
Latest Press Releases
View all
TimeHeadline
44m agoAs U.S. Markets Surge Like the Dot-Com Boom Era, ELEKTROS Inc. Celebrates a Powerful Rise in Global Momentum As Penny Stock and Microcap Investors Worldwide Continue Discovering the Company's Vision for Hard Rock Lithium Mining and EV Patent Technology
YesterdayDelivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
YesterdayRefers to Item 7 on the agenda: Report on the audit of the consolidated financial statements of Grupa Kęty SA
YesterdayThe 4th BOCHK Science and Technology Innovation Prize Award Ceremony Concludes with Great Success
YesterdayBuffalo Potash Files Annual Information Form and New Technical Report
Shionogi & Co., Ltd. logo

Shionogi & Co., Ltd.

About

2,959.50JPY-21.50 -0.72%
Closed • Updated at 17:44 GMT+00:00
Market Cap$16.37B
P/E Ratio12.28
Volume2.66M
Beta0.56
RSI33.51
Gross Margin82.28%
Health TechnologyPharmaceuticals: Major

Shionogi & Co., Ltd. — investor relations, events, news, and company updates on 6ix.

Latest News

Apr 8 2026
Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats
Apr 7 2026
ESCMID Global 2026: Shionogi Presents New Real-World Data Highlighting Clinical Effectiveness of Fetroja®/Fetcroja® (cefiderocol) in MBL-Producing Enterobacterales Infections
Apr 1 2026
Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)
Mar 24 2026
Apnimed Announces Strategic Monetization of Shionogi-Apnimed Sleep Science (SASS) Joint Venture Stake for $150M and Royalties, Strengthening Focus on its Wholly-Owned OSA Program, AD109
Mar 18 2026
BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025

Community Chat

Ask AI

Try asking
6ix6ix